A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 6, 1998, Pages 579-583

  Larner, J ^a   Jane, J ^a   Laws, E ^a   Packer, R ^a   Myers, C ^a   Shaffrey, M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cell cycle; Farnesylation; Lovastatin ras; Prenylation; Radiation; Sensitizer

Indexed keywords

MEVINOLIN; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DNA REPLICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; ENZYME INHIBITION; FEMALE; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRENYLATION; RADIOSENSITIZATION; SIGNAL TRANSDUCTION;

ADULT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MIDDLE AGED; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT;

EID: 0031793142     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199812000-00010     Document Type: Article

References (39)

1. Gunderson S, Lote K, Hannisdal E. Prognostic factors for glioblastoma multiforme-development of a prognostic index. Acta Oncol 1996;35(suppl 8):123-7.
2. Simpson J, Scott C, Rotman M, Curran W, Constine L, Fischbach A, Asbell S. Race and prognosis of brain tumor patients entering multicenter clinical trials. a report from the Radiation Therapy Oncology Group. Am J Clin Oncol 1996;19:114-20.
3. Petersdorf S, Livingston R. High dose chemotherapy for the treatment of malignant brain tumors. J Neurooncol 1994; 20:155-63.
4. Walker M, Alexander E Jr, Hunt W, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. a cooperative clinical trial. J Neurosurg 1978;49:333-43.
5. Grossman S, Norris L. Adjuvant and neoadjuvant treatment for primary brain tumors in adults. Semin Oncol 1995;22:530-9.
6. Lesser G, Grossman S. The chemotherapy of adult primary brain tumors. Cancer Treat Rev 1993;19:261-81.
7. Bernstein M, Laperriere N, Glen J. Stereotactic high-activity brachytherapy for malignant intra-axial brain tumors, status report as of March, 1995. Stereotact Funct Neurosurg 1995; 65:167-70.
8. Assietti R, Olson J. Intra-arterial cisplatin in malignant brain tumors: incidence and severity of otic toxicity. J Neurooncol 1996;27:251-8.
9. Gannett D, Stea B, Lulu B, Adair T, Verdi C, Hamilton A. Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas. Int J Radiat Oncol Biol Phys 1995;33:461-8.
10. Shrieve D, Alexander E, Wen P, Fine H, Kooy H, Black P, Loeffler J. Comparison of stereotactic radiosurgery and brachy-therapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995;36:275-82.
11. Brem H, Piantadosi S, Burger P, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 1995; 345:1008-12.
12. Buahin K, Brem H. Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. J Neurooncol 1995;26:103-10.
13. Kuroda R, Akai F, Iwasaki H, Nakatani J, Uchiyama T, Ioku M, Kaetsu I. Interstial chemotherapy with biodegradable ACNU pellet for glioblastoma. Stereotact Fund Neurosurg 1994; 63:154-9.
14. Micheletti E, Baroncell G, La Face B, Feroldi P, Galelli M, Giunta F. High-dose interstitial brachytherapy for glioblastoma multiforme. Tumori 1994;80:44-9.
15. Bernstein M, Lumley M, Davidson G, Laperriere N, Leung P. Intracranial arterial occlusion associated with high-activity iodine-125 brachytherapy for glioblastoma. J Neurooncol 1993;17:253-60.
16. Larner J, Phillips C, Dion J, Jensen M, Newman S, Jane J. A phase 1-2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas. Am J Clin Oncol 1995;18:1-7.
17. Fumagalli R, Grossi E, Paoletti P, Paoletti R. Studies on lipids in brain tumors. I. occurrence and significance of sterol precursors of cholesterol in human brain tumors. J Neurochem 1964;11:561-5.
18. Maltese W. 3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors. Neurology 1983;33:1294-9.
19. Maltese W, Defendini R, Green R, Sheridan K, Donley D. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest 1985;76:1748-54.
20. Resh M. Regulation of cellular signalling by fatty acid acylation and prenylation of signal transduction proteins. Cell Signal 1996;8:403-12.
21. Zhang F, Casey P. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-69.
22. Bernhard E, Kao G, Cox A, Sebti S, Hamilton A, Muschel R, McKenna W. The farnesyltransferase inhibitor FTI-277 radio-sensites H-ras-transformed rat embryo fibroblasts. Cancer Res 1996;56:1727-30.
23. Bishop W, Bond R, Petrin J, et al. Novel tricyclic inhibitors of farnesyl protein transferase. J Biol Chem 1995;270:30611-8.
24. 12 proteins to farnesyltransferase inhibitors in rat1 cells. Proc Natl Acad Sci U S A 1996;93:4454-8.
25. McKenna W, Weiss M, Bakanauskas V, et al. The Role of the H-Ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 1990;18:849-59.
26. ras isoprenylation. Int J Cancer 1993;53:302-7.
27. Sumi S, Beauchamp R, Townsend C, Pour P, Ishizuka J, Thompson J. Lovastatin inhibits pancreatic cancer growth regardless of ras mutation. Pancreas 1994;9:657-61.
28. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 1996;66:710-6.
29. Thibault A, Samid D, Tompkins A, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clinical Cancer Research 1996;2:483-91.
30. Pazzaglia S, Saran A, Pariset L, Rebessi S, Di Majo V, Coppola M, Covelli V. Sensitivity of C3H 10T 1/2 cells to radiation-induced killing and neoplastic transformation as a function of cell cycle. Int J Radiat Oncol Biol Phys 1996;69:57-65.
31. Langley R, Quartuccio S, Kennealey P, Coleman C, Bump E. Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation-induced apoptosis in F9 teratocarcinoma cells. Radiat Res 1995;144:90-6.
32. 1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997;272:13-6.
33. Lovastatin Study Groups I Through IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993;153:1079-87.
34. Kostis J, Rosen R, Wilson A. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on deep and cognitive performance in patients with hypercholestereolemia. J Clin Pharmacol 1994;34:989-96.
35. Samid D, Ram Z, Hudgins W, et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 1994;54:891-5.
36. Pineau T, Hudgins W, Liu L, Chen L, Sher T, Gonzalez F, Samid D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 1996;52:659-67.
37. Thibault A, Samid D, Cooper M, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 1995;75:2932-8.
38. Samid D, Shack S, Myers C. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993;91:2288-95.
39. Samid D, Shack S, Sherman L. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 1992;52:1988-92.